Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

House Dust Mite Disease Market to Exhibit Substantial Growth at a CAGR of 3.5% During the Forecast Period (2025-2034) | DelveInsight USA - English USA - English

prnewswire.com
ALKS ALK-Abello is mentioned as a key company with a marketed drug (ODACTRA/ACARIZAX/MITICURE) for house dust mite disease, indicating its presence in the market but without specific growth or decline indicators in the article. STG Stallergenes Greer is listed as a key company with a marketed drug (ACTAIR/ORYLMYTE/AITMYTE) for house dust mite disease, showing its involvement in the market without specific sentiment drivers. GSK GlaxoSmithKline is mentioned in the context of related asthma and allergic rhinitis markets, but not directly for house dust mite disease products in this article, thus sentiment is neutral. SNY Sanofi is mentioned in the context of related asthma and allergic rhinitis markets, but not directly for house dust mite disease products in this article, thus sentiment is neutral. TEVA Teva Pharmaceuticals is mentioned in the context of related asthma and allergic rhinitis markets, but not directly for house dust mite disease products in this article, thus sentiment is neutral. AZN AstraZeneca is mentioned in the context of related asthma and allergic rhinitis markets, but not directly for house dust mite disease products in this article, thus sentiment is neutral. INCY Incyte Corporation is mentioned in the context of related asthma markets, but not directly for house dust mite disease products in this article, thus sentiment is neutral. REGN Regeneron Pharmaceuticals is mentioned in the context of related asthma and allergic rhinitis markets, but not directly for house dust mite disease products in this article, thus sentiment is neutral. PFE Pfizer Inc. is mentioned in the context of related severe asthma and atopic dermatitis markets, but not directly for house dust mite disease products in this article, thus sentiment is neutral. BMY LLY AMGN Amgen Inc. is mentioned in the context of related severe asthma markets, but not directly for house dust mite disease products in this article, thus sentiment is neutral. ABBV GILD Gilead Sciences, Inc. is mentioned in the context of related severe asthma markets, but not directly for house dust mite disease products in this article, thus sentiment is neutral. BIIB Biogen Inc. is mentioned in the context of related severe asthma markets, but not directly for house dust mite disease products in this article, thus sentiment is neutral. CSL CSL Limited is mentioned in the context of related severe asthma markets, but not directly for house dust mite disease products in this article, thus sentiment is neutral. VRTX Vertex Pharmaceuticals Incorporated is mentioned in the context of related severe asthma markets, but not directly for house dust mite disease products in this article, thus sentiment is neutral. BHC Bausch Health Companies Inc. is mentioned in the context of related atopic dermatitis markets, but not directly for house dust mite disease products in this article, thus sentiment is neutral. NVS Novartis AG is mentioned in the context of related severe asthma markets, but not directly for house dust mite disease products in this article, thus sentiment is neutral. MRK Merck & Co., Inc. is mentioned in the context of related severe asthma markets, but not directly for house dust mite disease products in this article, thus sentiment is neutral. LEO ALLT Allergy Therapeutics is mentioned in the context of related allergic rhinitis markets, but not directly for house dust mite disease products in this article, thus sentiment is neutral. CNTB Connect Biopharma is mentioned in the context of related asthma markets, but not directly for house dust mite disease products in this article, thus sentiment is neutral. INM Inmunotek is mentioned as a key company with an emerging drug (MM09) for house dust mite disease and in related allergic rhinitis markets, indicating its involvement but without specific growth or decline indicators.

The house dust mite disease market is experiencing steady growth, driven by rising global prevalence of allergic rhinitis and asthma linked to indoor allergens. Increasing adoption of allergen-specific immunotherapies, including sublingual tablets, is expanding treatment options and fueling market demand. Additionally, the launch of emerging therapies such as HAL Allergy's PURETHAL Mites, Probelte Pharma's BELTAVAC, Inmunotek's MM09, T-Balance Therapeutics' tregalizumab, and others will further drive the market forward.

LAS VEGAS, Jan. 14, 2026 /PRNewswire/ -- DelveInsight's House Dust Mite Disease Market Insights report includes a comprehensive understanding of current treatment practices, house dust mite disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, Japan, and China].

House Dust Mite Disease Market Summary

Discover the new house dust mite disease treatment @ https://www.delveinsight.com/sample-request/house-dust-mite-disease-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr

Key Factors Driving the Growth of the House Dust Mite Disease Market

House Dust Mite Disease Market Analysis

House Dust Mite Disease Competitive Landscape

The emerging pipeline of HDMD holds a few products in development by prominent key players such as HAL Allergy (PURETHAL Mites), Probelte Pharma (BELTAVAC), Inmunotek (MM09), T-Balance Therapeutics (tregalizumab), and others.

HAL Allergy's PURETHAL Mites is a subcutaneous allergen immunotherapy that employs a chemically modified house dust mite (HDM) extract, Dermatophagoides pteronyssinus and Dermatophagoides farinae, adsorbed onto aluminum hydroxide. The therapy is currently being evaluated in a Phase III clinical trial.

Probelte Pharma's BELTAVAC is a subcutaneous immunotherapy indicated for the treatment of Alternaria mold allergy. Developed by Probelte Pharma, it is a safer allergen immunotherapy based on a Dermatophagoides pteronyssinus dust mite extract that has been chemically altered through glutaraldehyde polymerization. This product is also in Phase III clinical development.

The anticipated launch of these emerging therapies are poised to transform the house dust mite disease market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the house dust mite disease market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Discover more about the house dust mite disease drugs @ House Dust Mite Disease Drugs Market

Recent Developments in the House Dust Mite Disease Market

What is House Dust Mite Disease?

House dust mite disease (HDMD) is a chronic allergic condition caused by an immune hypersensitivity to proteins found in the feces and body fragments of house dust mites. These microscopic arthropods thrive in indoor environments, including bedding, carpets, and upholstered furniture. In sensitized individuals, exposure to these allergens triggers an IgE-mediated inflammatory response, leading to symptoms that commonly affect the upper and lower airways, including allergic rhinitis, nasal congestion, sneezing, itchy or watery eyes, chronic cough, and asthma exacerbations. HDMD is a major contributor to perennial allergic respiratory disease worldwide, with symptoms often persisting year-round due to continuous indoor exposure, significantly impacting quality of life, sleep, productivity, and long-term respiratory health.

House Dust Mite Disease Epidemiology Segmentation

The house dust mite disease epidemiology section provides insights into the historical and current house dust mite disease patient pool and forecasted trends for the leading markets. HDM allergy is present in up to 90% of Asian atopic patients, far exceeding that which is seen in Western populations, which report a prevalence of only 50 to 70%.

The house dust mite disease treatment market report proffers epidemiological analysis for the study period 2020–2034 in the leading markets, segmented into:

House Dust Mite Disease Market Report Metrics

Details

Study Period

2020–2034

Coverage

8MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, Japan, and China].

House Dust Mite Disease Market CAGR

3.5 %

House Dust Mite Disease Market Size in 2024

USD 9.2 Billion

Key House Dust Mite Disease Companies

HAL Allergy, Probelte Pharma, Inmunotek, T-Balance Therapeutics, ALK-Abello, Stallergenes Greer, and others

Key House Dust Mite Disease Therapies

House dust mite allergy vaccine (PURETHAL Mites), Alternaria allergy immunotherapy (BELTAVAC), MM09, Tregalizumab, ODACTRA/ACARIZAX/MITICURE, ACTAIR/ORYLMYTE/AITMYTE, and others

Scope of the House Dust Mite Disease Market Report

Download the report to understand what is the latest research on house dust mite disease @ New House Dust Mite Disease Medication

Table of Contents

1

House Dust Mite Disease Market Key Insights

2

House Dust Mite Disease Market Report Introduction

3

Executive Summary of HDMD

4

Key Events

5

Epidemiology and Market Forecast Methodology

6

HDMD Market Overview at a Glance

6.1

Clinical Landscape (Analysis by Molecule Type, Phase, and Route of Administration [RoA])

6.2

Market Share of HDMD by Therapies (%) in the 7MM + China in 2024

6.3

Market Share of HDMD by Therapies (%) in the 7MM + China in 2034

7

Disease Background and Overview

7.1

Introduction

7.2

House Dust Mite Allergic Disorders

7.2.1

Allergic Asthma

7.2.2

Allergic Rhinitis

7.2.3

Atopic Dermatitis

7.3

Symptoms

7.4

Diagnosis

8

House Dust Mite Disease Treatment

9

Epidemiology and Patient Population

9.1

Key Findings

9.2

Assumptions and Rationales

9.3

Total Diagnosed Prevalent Population of Asthma in the 7MM + China

9.4

Total Diagnosed Prevalent Population of Allergic Rhinitis in the 7MM + China

9.5

Total Diagnosed Prevalent Population of Atopic Dermatitis in the 7MM + China

9.6

Total Diagnosed Prevalent Population of HDMD in the 7MM + China

9.7

The United States

9.7.1

Total Prevalent Population of HDMD in the United States

9.7.2

Total Diagnosed Prevalent Population of HDMD in the United States

9.7.3

Gender-specific Diagnosed Prevalent Population of HDMD in the United States

9.7.4

Allergen-specific Diagnosed Prevalent Population of HDMD in the United States

9.7.5

Total Treated Cases of HDMD in the United States

9.8

EU4 and the UK

9.9

Japan

9.10

China

10

House Dust Mite Disease Patient Journey

11

Marketed House Dust Mite Disease Drugs

11.1

Key Cross Competition

11.2

Dermatophagoides farinae and Dermatophagoides pteronyssinus (ODACTRA/ACARIZAX/MITICURE): ALK-Abello

11.2.1

Product Description

11.2.2

Regulatory Milestones

11.2.3

Other Developmental Activities

11.2.4

Summary of Pivotal Trials

11.2.5

Clinical Development

11.2.6

Analyst Views

11.3

House dust mite allergen extract (ACTAIR/ORYLMYTE/AITMYTE): Stallergenes Greer

12

Emerging House Dust Mite Disease Drugs

12.1

Key Cross Competition

12.2

House Dust Mite Allergy Vaccine (PURETHAL Mites): HAL Allergy

12.2.1

Product Description

12.2.2

Clinical Development

12.3

Alternaria Allergy Immunotherapy (BELTAVAC): Probelte Pharma

12.4

MM09: Inmunotek

12.5

Tregalizumab: T-Balance Therapeutics

13

HDMD Market: 7MM + China Analysis

13.1

Key Findings

13.2

Total Market Size of HDM in the 7MM + China

13.3

House Dust Mite Disease Market Outlook

13.4

Conjoint Analysis

13.5

Key House Dust Mite Disease Market Forecast Assumptions

13.6

The United States House Dust Mite Disease Market Size

13.6.1

Total Market Size of HDMD in the United States

13.6.2

Total Market Size of HDMD by Therapies in the United States

13.7

EU4 and the UK House Dust Mite Disease Market Size

13.8

Japan House Dust Mite Disease Market Size

13.9

China House Dust Mite Disease Market Size

14

House Dust Mite Disease Market Unmet Needs

15

House Dust Mite Disease Market SWOT Analysis

16

KOL Views on House Dust Mite Disease

17

House Dust Mite Disease Market Access and Reimbursement

17.1

The United States

17.2

In EU4 and the UK

17.3

Japan

17.4

Summary and Comparison of Market Access and Pricing Policy Developments in 2025

17.5

Market Access and Reimbursement of HDMD Therapies

18

Bibliography

19

House Dust Mite Disease Market Report Methodology

Related Reports

Asthma Market

Asthma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key asthma companies including GlaxoSmithKline, Areteia Therapeutics, Sanofi, Connect Biopharma, Upstream Bio, Teva Pharmaceuticals, Launch Therapeutics, AstraZeneca, Incyte Corporation, among others.

Severe Asthma Market

Severe Asthma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key severe asthma companies including AstraZeneca plc, GlaxoSmithKline plc, Sanofi S.A., Novartis AG, Roche Holding AG, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals, Inc., Johnson & Johnson, Pfizer Inc., Bristol Myers Squibb, Eli Lilly and Company, Vertex Pharmaceuticals Incorporated, Amgen Inc., AbbVie Inc., Genentech, Inc., Gilead Sciences, Inc., Biogen Inc., CSL Limited, among others.

Allergic Rhinitis Market

Allergic Rhinitis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key allergic rhinitis companies including Inmunotek, Emergo Therapeutics, AOBiome LLC, Regeneron Pharmaceuticals, Revolo Biotherapeutics, Allergy Therapeutics, among others.

Atopic Dermatitis Market

Atopic Dermatitis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key atopic dermatitis companies including Bausch Health Companies Inc., GlaxoSmithKline PLC, Nestle SA, Pfizer Inc., Regeneron Pharmaceuticals Inc., Evelo Biosciences, Abbvie Inc., Allergan PLC, Cara Therapeutics, Bristol-Myers Squibb Company, Sanofi S.A., LEO Pharma, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur

[email protected]

+14699457679

www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research, LLP